Patents by Inventor Michael C. Quirk

Michael C. Quirk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20250064833
    Abstract: The present disclosure relates to compositions, kits, and methods of treating CNS diseases and disorders using a combination of a muscarinic receptor positive modulator and an NMDA receptor positive allosteric modulator.
    Type: Application
    Filed: December 13, 2022
    Publication date: February 27, 2025
    Inventors: Michael C. Quirk, Aaron Michael Koenig
  • NEUROACTIVE STEROID FOR THE TREATMENT OF HUNTINGTON'S DISEASE
    Publication number: 20250041317
    Abstract: Provided herein are methods for improving working memory and/or executive function in a subject suffering from Huntington's Disease, comprising administering to the subject SAGE-718, an investigational positive allosteric modulator of the NMDA receptor.
    Type: Application
    Filed: December 12, 2022
    Publication date: February 6, 2025
    Inventors: Michael C. Quirk, Aaron Michael Koenig
  • NEUROACTIVE STEROID FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT ASSOCIATED WITH PARKINSON'S DISEASE
    Publication number: 20240252514
    Abstract: Provided herein are methods for improving working memory and/or executive function in a subject suffering from Parkinson's Disease, comprising administering to the subject a compound having the formula.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 1, 2024
    Inventors: James J. Doherty, Michael C. Quirk, Aaron Michael Koenig, Jason Karl Johannesen
  • NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20230218638
    Abstract: Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.
    Type: Application
    Filed: September 19, 2022
    Publication date: July 13, 2023
    Inventors: Michael C. Quirk, James J. Doherty, Gabriel Martinez Botella
  • NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170304321
    Abstract: Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Michael C. Quirk, James J. Doherty, Cabriel Martinez Botella